Understanding the presence and function of erythropoietin receptors on cancer cells

Journal of Clinical Oncology

Volumn 24, Issue 29, 2006, Pages 4675-4676

  Lai, Stephen Y ^a   Grandis, Jennifer R ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN RECEPTOR; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER; CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EDITORIAL; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; DISEASE COURSE; DRUG EFFECT; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOPLASM; NOTE; TREATMENT OUTCOME;

DISEASE PROGRESSION; ERYTHROPOIETIN; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; RECEPTORS, ERYTHROPOIETIN; TREATMENT OUTCOME;

EID: 33750588361     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.1190     Document Type: Editorial

References (28)

1. Hardee M, Arcasoy M, Blackwell K, et al: Erythropoietin biology in cancer. Clin Cancer Res 12:332-339, 2006
2. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
3. Shasha D: The negative impact of anemia on radiotherapy and chemoradiation outcomes. Semin Hematol 38:8-15, 2001
4. Caro JJ, Salas M, Ward A, et al: Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 91:2214-2221, 2001
5. Spivak JL: The anaemia of cancer: Death by a thousand cuts. Nat Rev Cancer 5:543-555, 2005
6. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23:5960-5972, 2005
7. Henke M, Laszig R, Rube C, et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind placebo-controlled trial. Lancet 362:1255-1260, 2003
8. Correspondences: Lancet 363:78-82; 992-994, 2004
9. Henke M, Mattern D, Pepe M, et al: Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24:4708-4713, 2006
10. Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. JAMA 293:90-95, 2005
11. Yasuda Y, Masuda S, Chikuma M, et al: Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 273:25381-25387, 1998
12. Sakanaka M, Wen TC, Matsuda S, et al: In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95:4635-4640, 1998
13. Hanlon PR, Fu P, Wright GL, et al: Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: Role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 19:1323-1325, 2005
14. Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24:2666-2672, 2006
15. Lester RD, Jo M, Campana WM, et al: Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 280:39273-39277, 2005
16. Kumar S, Yu H, Fong D, et al: Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res 16:275-283, 2006
17. Mohyeldin A, Lu H, Dalgard C, et al: Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 7:536-543, 2005
18. Lai SY, Childs EE, Xi S, et al: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24:4442-4449, 2005
19. Bittorf T, Buchse T, Sasse T, et al: Activation of the transcription factor NF-kappaB by the erythropoietin receptor: Structural requirements and biological significance. Cell Signal 13:673-681, 2001
20. Pajonk F, Weil A, Sommer A, et al: The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 23:8987-8991, 2004
21. Acs G, Zhang PJ, McGrath CM, et al: Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression Am J Path 162:1789-1806, 2003
22. Anagnostou A, Lee ES, Kessimian N, et al: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 87:5978-5982, 1990
23. Yasuda Y, Fujita Y, Matsuo T, et al: Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021-1029, 2003
24. Belenkov AI, Shenouda G, Rizhevskaya E, et al: Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 3:1525-1532, 2004
25. Wesphal G, Niederberger E, Blum C, et al: Erythropoietin and G-CSF receptors in human tumor cells: Expression and aspects regarding functionality. Tumori 88:150-159, 2002
26. Mittelman M, Neumann D, Peled A, et al: Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 98:5181-5186, 2001
27. Tovari J, Gilly R, Raso E, et al: Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res 65:7186-7193, 2005
28. Miller CB, Jones RJ, Piantadosi S, et al: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1692, 1990